The effects of a soluble trimeric CD40 ligand (CD40L) agonist on the expression of CD4 and CCR5 and on human immunodeficiency virus (HIV) type 1 entry into and replication in human macrophages were investigated. CD40L increased the number of CD4 and CCR5 antibody-binding sites and the percentage of CD4-and CCR5-expressing cells. Infection of CD40L-stimulated macrophages with HIV-1 resulted in a marked increase of viral DNA with respect to controls, as demonstrated by polymerase chain reaction assay. HIV-1 p24 antigen analysis showed that peak viral production did not differ between CD40L-stimulated macrophages and controls. However, because of a prolonged life span, overall viral output was increased in CD40L-stimulated cultures. In addition, CD40L down-regulated the antiviral efficacy of compounds that inhibit HIV-1 reverse transcriptase. In conclusion, CD40L stimulation of macrophages can contribute to plasma virus load and favor the establishment of a pool of latently infected macrophages that can be reactivated to release virus.
The effects of a soluble trimeric CD40 ligand (CD40L) agonist on the expression of CD4 and CCR5 and on human immunodeficiency virus (HIV) type 1 entry into and replication in human macrophages were investigated. CD40L increased the number of CD4 and CCR5 antibody-binding sites and the percentage of CD4-and CCR5-expressing cells. Infection of CD40L-stimulated macrophages with HIV-1 resulted in a marked increase of viral DNA with respect to controls, as demonstrated by polymerase chain reaction assay. HIV-1 p24 antigen analysis showed that peak viral production did not differ between CD40L-stimulated macrophages and controls. However, because of a prolonged life span, overall viral output was increased in CD40L-stimulated cultures. In addition, CD40L down-regulated the antiviral efficacy of compounds that inhibit HIV-1 reverse transcriptase. In conclusion, CD40L stimulation of macrophages can contribute to plasma virus load and favor the establishment of a pool of latently infected macrophages that can be reactivated to release virus.
Cells belonging to the monocyte-macrophage lineage play a crucial role in the pathogenesis and progression of human immunodeficiency virus (HIV) type 1 infection [1] . Monocytemacrophages are a major target for HIV-1 infection in the body, as shown by infection of blood monocytes, macrophages in spleen and lymph nodes, alveolar macrophages of the lung, Langerhans' cells of the skin, Kupffer's cells of the liver, and macrophage-like cells in the central nervous system [2] [3] [4] [5] [6] [7] [8] .
Macrophages express CD40, a 50-kDa glycoprotein receptor for the CD40 ligand (CD40L; also called CD154), a cell surface molecule present primarily on activated T cells [9, 10] . CD40/ CD40L costimulation plays a major role in regulating cellular immune responses. Interactions between CD40 on antigen-presenting cells and CD40L on activated T cells results in the priming and expansion of antigen-specific CD4 + T cells, induction of costimulatory molecules on antigen-presenting cells, and the release of cytokines [11] [12] [13] [14] [15] . Several elements of this pathway have been implicated in the spectrum of immunologic dysfunction associated with HIV-1 infection [16, 17] . More important, CD40L recently has been found to modulate the expression of CD4 and the HIV-1 coreceptors CCR5 and CXCR4 in a variety of cell types and to enhance the replication of HIV-1 in dendritic cells and in B cells [18] [19] [20] ; yet, CD40/CD40L costimulation has also been reported to induce the release of chemokines having suppressive effects on HIV-1 infection [21] [22] [23] . With this background, the present set of experiments was designed to study the ability of a soluble trimeric CD40L agonist to modulate the replication of macrophage-trophic variants of HIV-1 in cultured human macrophages.
Materials and Methods
Compounds. Soluble trimeric recombinant CD40L was provided by Immunex, and macrophage colony-stimulating factor (M-CSF) containing 2 £ 10 6 U/mg protein was provided by Genetics Institute. Zidovudine was purchased from Sigma Chemical, and 23f, a novel nonnucleoside reverse-transcriptase (RT) inhibitor [24] , was a gift from G. Campiani (Dipartimento di Scienze Farmaceutiche, Università degli Studi di Siena, Siena, Italy).
Viruses. A macrophage-trophic laboratory strain (Ba-L), which strictly uses CCR5 as coreceptor, and 3 clinical isolates of HIV-1 were used to infect macrophages. Supernatants of infected macrophages were used as the source of HIV-1 Ba-L . These were filtered and stored in liquid nitrogen before use. The clinical isolates of HIV-1 (a gift from M. Andreoni, Department of Public Health and Cellular Biology, University of Rome "Tor Vergata," Rome) were obtained from 3 HIV-seropositive persons. Isolation of these strains from the plasma of infected individuals was performed in peripheral blood mononuclear cell (PBMC) cultures; the supernatants of these cultures were used as the source of the virus. The strains (FB1, FB2, and FB3) replicate in primary lymphocytes and macrophages but not in transformed cell lines. Titration to determine infectivity of HIV-1 Ba-L and of primary isolates, respectively, was performed in a primary macrophage system and in PBMC, as described elsewhere [25, 26] . The titer of the virus stocks, expressed as TCID 50 , was determined, as described elsewhere [27] .
Virus detection. HIV p24 antigen production in supernatants was assessed by use of a sandwich ELISA (Abbott). RT activity was assayed, using reaction conditions similar to those of Abrell and Gallo [28] . In brief, 10 mL of supernatant was incubated in a reaction mixture containing 0.05% Nonidet P-40, 5 mM dithiothreitol, 50 oligo(dT) [12] [13] [14] [15] [16] [17] [18] (Pharmacia). Radiolabeled nucleotides were precipitated with cold trichloroacetic acid on paper filters in an automatic cell harvester and washed with 95% ethanol. Radioactivity was estimated by liquid scintillation spectroscopy. Cells. Peripheral blood obtained from HIV-negative donors was enriched for PBMC by centrifugation over ficoll-hypaque (Nycomed Pharma). PBMC were then further enriched for monocytes by elutriation [29] . Cells obtained by this method are .90% monocytes, as determined by fluorescence-activated cell sorter (FACS; Becton Dickinson) analysis. The cells were cultured in 48-well plates (Costar) in complete medium (RPMI-1640 supplemented with 20% heat-inactivated fetal calf serum [FCS], 2 mM L-glutamine, 50 U/mL penicillin, and 50 mg/mL streptomycin) at 2 £ 10 5 cells/ well/mL at 37 C in a humidified atmosphere of 5% CO 2 in air. Each experiment was done using PBMC from a single donor.
Infection of macrophages with HIV-1. Freshly elutriated monocytes were allowed to mature into macrophages for 7 days in the presence or absence of 1 mg/mL CD40L. At day 7, cultures were washed, refed with fresh complete medium containing 1 mg/mL CD40L, and infected for 2 h with 300 ID 50 of the different HIV-1 isolates. In selected experiments, macrophages were infected in the presence of various concentrations of zidovudine, 23f, or U75875. Appropriate mock-infected cultures were run as a control. After infection, the cells were extensively washed to remove excess virus and were cultured in complete medium with or without CD40L and drugs, as before.
Detection of macrophage inflammatory protein (MIP)-1a and -1b, RANTES, tumor necrosis factor (TNF)-a, interleukin (IL)-1b, M-CSF, and granulocyte-macrophage colony-stimulating factor (GM-CSF). Monocytes were cultured for 7 days in the presence or absence of 1 mg/mL CD40L. Culture fluids were collected for chemokine, cytokine, and growth factor determination at days 1, 3, 5, and 7. Chemokine, cytokine, and growth factor production was assayed by use of ELISA kits (Quantikine; R&D System).
FACS analysis. For CD4 and CCR5 expression analysis, cells were recovered, washed, resuspended in PBS, and stained for 15 min with fluorescein isothiocyanate-conjugated mouse anti-human CD4 and phycoerythrin (PE)-conjugated mouse anti-human CCR5 (both from PharMingen). Paired isotype-specific control antibodies (PharMingen) were run with each sample. FACS analysis of intracellular HIV p24 antigen was performed, as described elsewhere [30] . In brief, at given time points (see Results), the cultures were washed and refed with complete medium containing 1 mg/mL brefeldin A, a protein transport inhibitor. Eighteen hours after the addition of brefeldin A, the cells were washed twice in PBS, detached by gentle scraping, collected by centrifugation, and fixed in 4% paraformaldehyde at 4 C for 15 min. After 2 further washes, the cells were resuspended for 30 min at room temperature in 30 mL of PBS containing 0.1% saponin, 1% bovine serum albumin, and 0.5 mg/10 6 cells of PE-conjugated mouse anti-HIV p24 antigen (Immunotech). As a last step, the cells were washed twice in PBS containing 0.01% saponin. Paired isotypespecific control antibodies (PharMingen) were run with each sample. FACS analysis was performed using a FACScan flow cytometer (Becton Dickinson). Five thousand cells were computed in list mode and were analyzed using FACScan research software (Becton Dickinson). Macrophages were differentiated from lymphocytes and dead cells on the basis of forward angle and 90 scatter; 5000 cells were analyzed for each sample.
Quantitative FACS analysis. Quantitative FACS analysis was performed by converting the mean channel fluorescence into antibodybinding sites by use of a standardized microbeads kit (Sigma), as described elsewhere [31] . PE-conjugated mouse anti-human CD4 and CCR5 antibodies were used for this analysis. Details on the relationship between antibody-binding sites and mean fluorescence intensity values can be obtained from the manufacturer.
HIV DNA amplification. Macrophages were infected, as described above, and detached from the wells 48 h after viral challenge. DNA was extracted, as described elsewhere [32] . Integrated DNA was separated by fractionation of total cell DNA into high-and low-molecular mass portions by agarose gel electrophoresis in low-melting point agarose. The high-molecular mass DNA fraction containing chromosomal DNA and integrated viral DNA was recovered by agarose digestion (AgarACE Enzyme; Promega). After spectrophotometric quantitation (GeneQuant II; Pharmacia), end-point dilutions of the DNA from each sample were subjected either to 33 cycles of polymerase chain reaction (PCR) amplifications, using the HIV gag primer pair SK38/SK39 or the long terminal repeat (LTR) R/U5 primer [33] , or to 27 cycles, using the HLA-DQa1 primer pair GH26/GH27, in a total volume of 100 mL. The HIV-positive control was plasmid DNA (Perkin-Elmer Cetus) containing the entire rearranged genome of the HIV Z6 isolate. The amplifications were performed in an automated temperature-cycling device (DNA Thermal Cycler 480; PerkinElmer Cetus), using a recombinant, thermostable DNA polymerase (AmpliTaq Gold; Perkin-Elmer). The SK19, LTR R/U5 [33] , and RH54 oligonucleotide probes were end-labeled with [ 32 P]-adenosine triphosphate, and the amplified products of the correct size were specifically detected by the oligomer hybridization procedure, as described elsewhere [34, 35] .
Assessment of cell viability. The number of live cells was determined by use of the trypan blue assay. Propidium iodide staining and flow cytometric analysis were employed to quantify the percentage of necrotic cells. In brief, at given time points, the cells were washed twice in PBS, detached by gentle scraping, and collected by low-speed centrifugation. The centrifuged cell pellet was gently resuspended in 0.5 mL of PBS containing 2 mg/mL propidium iodide (Sigma). Propidium iodide fluorescence of individual cells was measured by flow cytometry (FACScan; Becton Dickinson). The red fluorescence due to propidium iodide staining of the DNA was registered on a logarithmic scale. Propidium iodide penetrates only necrotic cells, resulting in a peak of bright red fluorescence. The forward and side scatter of particles were measured simultaneously. Cell debris was excluded from analysis by appropriately raising the forward scatter threshold. At least 104 cells of each sample were analyzed.
CD40L inhibition assay. In some experiments, a mouse monoclonal antibody, anti-CD40L (Calbiochem), that functionally blocks CD40L-induced B cell proliferation and T cell-dependent B cell differentiation was preincubated with CD40L in a weight ratio of 1:1 for 30 min at 37 C. The mixture was then added to the cultures just after isolation, and its effect on CD4 and CCR5 expression was compared with that of CD40L alone.
Limulus amebocyte lysate test. All the compounds and media used in this study were analyzed for endotoxin contamination by the limulus amebocyte lysate test (QCL-1000; BioWhittaker). All the samples analyzed were free of endotoxin contamination (, 0.1 EU/mL).
Statistics. Student's t test was used to analyze data. P , :05 was considered to be significant.
Results
Modulation of CD4 and CCR5 levels on macrophages by CD40L. We first examined the effect of CD40L on the expression of CD4 and CCR5. Cells were cultured for 7 days in the presence of FCS or M-CSF alone or with the addition of CD40L. Alternatively, CD40L was given as a single dose at the time of cell plating or at the time of viral infection. The number of positive cells and antibody-binding sites for CD4 and CCR5 was monitored over time (table 1; figure 1A and 1B).
Macrophage maturation in FCS alone did not significantly affect the expression of CD4 and CCR5, which is consistent with previously reported flow cytometric data [31] . Addition of CD40L to the culture at the time of cell plating resulted in a significant increase in both CD4-and CCR5-positive cells and in the absolute numbers of receptors with respect to FCS alone, irrespective of whether cells were cultured in the continuous presence of CD40L or whether CD40L was given as a single dose at the time of cell plating (P . :05 for both types of treatment). However, when CD40L was added on day 7 of culture, no significant effect on receptor expression could be documented with respect to cells cultured in the presence of FCS alone. The effect of CD40L on receptor expression was abolished by preincubation with a specific antihuman CD40L antibody (data not shown).
In selected experiments, we analyzed the effect of CD40L on CD4 and CCR5 expression in macrophages cultured in the presence of M-CSF, a very potent macrophage-trophic and activating factor. As shown in table 1 and figure 1A, M-CSF stimulation resulted in an increased percentage of cells expressing CD4 and CCR5 and of antibody-binding sites for CD4 and CCR5, compared with macrophages cultured in the presence of CD40L alone. Of interest, this increased expression was virtually eliminated in macrophages matured in the presence of both M-CSF and CD40L. These results indicate that the effect of CD40L on HIV receptor expression on macrophages may depend on the state of activation or maturation of these cells.
Effect of CD40L stimulation on b-chemokine, proinflammatory cytokine, and CSF production by macrophages. On CD40L stimulation, macrophages produce soluble factors, including bchemokines, proinflammatory cytokines, and CSFs, which may regulate HIV-1 infection in these cells. Therefore, we next examined the effect of CD40L on macrophage secretory function. The amount of the different soluble factors found in the supernatants was normalized for the number of live cells. As shown in figure 2 , treatment of cells with CD40L resulted in significant production of b-chemokines (MIP-1a, MIP-1b, and RANTES) and proinflammatory cytokines (TNF-a and IL-1b) over the background level of unstimulated cultures (P , :001 for each factor tested). In contrast, CD40L did not induce significant production of M-CSF and GM-CSF with respect to control cells.
Stimulation of macrophages with CD40L increases HIV-1 DNA synthesis and integration. A growing body of evidence indicates that the entry of macrophage-trophic HIV-1 into cells depends on the cell surface expression of CD4 and CCR5 [36] [37] [38] [39] . In our experimental setting, CD40L up-modulated the expression of CD4 and CCR5; thus, we asked whether CD40L also increased the entry of HIV-1 Ba-L , which can use CCR5 in addition to CD4. DNA PCR was performed to identify early (LTR R/U5 primers) and late (SK38/SK39 gag primers) viral cDNA products of RT. Samples were collected 48 h after infection, a time period that allows the accumulation of both early and late RT [33] . HIV DNA was detected in untreated and CD40L-stimulated macrophages; however, limiting-dilution analysis by PCR showed that viral DNA increased~5-fold in CD40L-stimulated CD4  26^12  24^9  2 2^9  2 0^7  CCR5  6^2  9^3  7^4  7^3  CD4/CCR5  4^2  8^3  5^1  4^1  CD40L   a   CD4  70^22  83^31  78^27  75^26  CCR5  31^18  67^24  60^19  63^22  CD4/CCR5  22^9  4 2^16  46^14  50^17  CD40L   b   CD4  68^19  69^21  63^20  61^20  CCR5  27^12  60^18  56^13  60^20  CD4/CCR5  18^6  4 8^15  44^15  45^12  CD40L   c   CD4  NA  NA  25^8  2 2^11  CCR5  NA  NA  5^2  3^2  CD4/CCR5  NA  NA  3^1  3^2  M-CSF  CD4  95^11  98^15  92^13  96^0  CCR5  63^11  81^14  83^10  85^16  CD4/CCR5  58^13  66^18  64^9  7 2^11  M-CSF + CD40L  CD4  67^8  7 5^22  69^24  67^17  CCR5  28^20  55^15  52^17  51^19  CD4/CCR5  18^11  36^21  39^18  36^13 NOTE. The percentage of cells expressing CD4 and CCR5 was determined by fluorescence-activated cell sorter analysis of treated macrophage cultures. Data are the mean of 3 independent experiments performed with cells from 3 donors. FCS, fetal calf serum; NA, not applicable.
a Cells cultured in the continuous presence of CD40L. b Cells cultured with CD40L given as a single dose for 48 h at the time of cell plating.
c Cells cultured with CD40L given as a single dose for 48 h at day 7 of culture. Figure 1 . Effects of CD40 ligand (CD40L) on CD4 and CCR5 expression on macrophages. Absolute nos. of CD4 and CCR5 were determined by quantitative fluorescence-activated cell sorter analysis of macrophages cultured in the presence of fetal calf serum alone (A), in the continuous presence of CD40L (B), with CD40L given as a single dose for 48 h at the time of cell plating (C), with CD40L given as a single dose for 48 h on day 7 of culture (D), in the continuous presence of macrophage colony-stimulating factor (M-CSF) alone (E), and in the continuous presence of M-CSF plus CD40L (F). Data from 3 donors in 3 independent experiments were used for this analysis. Error bars represent SEs. At day 7 of culture, macrophages were stained with fluorescein isothiocyanate (FITC)-conjugated mouse anti-human CD4 and phycoerythrin (PE)-conjugated mouse anti-human CCR5 and analyzed on FL1 (FITC conjugated) vs. FL2 (PE conjugated) 2-dimensional plots to discriminate positive cells. Paired isotype-specific control antibodies were run with each sample. The data are representative of a typical experiment. macrophages with respect to untreated cells (figure 3). Of note, a similar increase in HIV DNA synthesis was detected in CD40L-stimulated macrophages compared with unstimulated controls, whether LTR R/U5 or SK38/SK39 gag primers were used. This indicates that CD40L up-modulates viral entry in macrophages without affecting the ability of HIV to complete the retrotranscription process.
CD40L Increases
After completion of RT, nuclear import of preintegration complexes and integration of viral DNA in host cell DNA occur, and these are critical steps in the establishment of a productive infection. To control for efficiency of viral DNA integration, chromosomal DNA was separated from total DNA by agarose gel electrophoresis and then was analyzed by limiting-dilution PCR for HIV DNA. As shown in figure 3 , a greater amount of integrated viral DNA was detected in CD40L-stimulated macrophages than in control cells. Comparable amplification of a fragment of the HLA-DQa1 gene was obtained from each macrophage sample, suggesting that the same amount of DNA was subjected to amplification (data not shown).
Of interest, in macrophages treated with both M-CSF and CD40L, the reduced CD4 and CCR5 expression with respect to M-CSF-treated cells was associated with decreased viral entry, as demonstrated by limiting-dilution PCR analysis of early (LTR R/U5) RTs (figure 4).
HIV-1 replication in CD40L-treated macrophages. We asked whether the ability of CD40L to augment the expression of CD4 and CCR5 and the synthesis and integration of HIV DNA was associated with increased viral production. Macrophages were infected with a macrophage-trophic laboratory strain (Ba-L) and 3 macrophage-trophic variants (FB1, FB2, and FB3) of HIV-1. As shown in figure 5 , both in the presence and absence of CD40L, viral production was detectable no earlier than day Figure 2 . Effect of CD40 ligand (CD40L) stimulation on b-chemokine, proinflammatory cytokine, and colony-stimulating factor production by macrophages. Cells were cultured in the presence or absence of 1 mg/mL CD40L for 7 days. Beginning on day 3 and every 2 days thereafter, supernatants were collected for quantitation of soluble factors. The data represent the mean of 2 experiments with 2 different donors, each carried out in triplicate (differences among the experiments were , 20%). Error bars represent SEM. FCS, fetal calf serum; GM-CSF, granulocytemacrophage colony-stimulating factor; IL, interleukin; M-CSF, macrophage colony-stimulating factor; MIP, macrophage inflammatory protein; TNF, tumor necrosis factor. 7 and then increased until day 21, with the overall curve of HIV p24 antigen production in supernatants from CD40L-stimulated macrophages being superimposable on that obtained using control macrophages. Then, a substantial waning in viral production occurred in control macrophages but not in CD40L-stimulated cultures, which maintained their ability to produce large amounts of virus at least up to day 35. Similar results were obtained in an additional experiment using the macrophage-trophic HIV-1 strain HIV-1 ADA (data not shown). In selected experiments, CD40L was added to the cultures 24 h after viral infection to evaluate its effect on ongoing viral infection; however, even under these experimental conditions, CD40L had no significant effect on peak viral output (figure 6).
Consistent with the ability of CD40L to enhance macrophage survival [14] , the number of cells at days 28 and 35 after infection ranged up to 2.8-and 5.3-fold higher, respectively, for macrophages stimulated by CD40L, compared with unstimulated cells (table 2) . In contrast, the percentage of HIV-1-infected cells, as demonstrated by FACS analysis, was not different between the 2 treatments (table 2) . This may explain the difference between viral production in CD40L-stimulated and unstimulated cultures at late time points.
Effect of CD40L treatment on the anti-HIV-1 activity of compounds that inhibit HIV RT. Last, we evaluated the effect of CD40L stimulation on the antiviral activity of compounds that block viral DNA formation by competing with HIV-1 RT (1 nucleoside analogue, zidovudine, and a nonnucleoside analogue, 23f). U75857, an inhibitor of viral protease, was used as a control. The results obtained are shown in figure 7 . The ED 50 , calculated as described elsewhere [40] for zidovudine and 23f in unstimulated macrophages, was 0.0072 mM and 0.0021 mM, respectively, whereas it increased to 0.064 mM and 0.016 mM when these macrophages were stimulated with CD40L (P , :05). By contrast, when we tested the effect of CD40L on U75875, we found that there was no modification of anti-HIV-1 activity (ED 50 for U75875 in control cells and CD40L-stimulated macrophages, Figure 3 . Limiting-dilution polymerase chain reaction amplification and oligomer-hybridization analysis of total and integrated viral DNA in human immunodeficiency virus (HIV) type 1-infected macrophages stimulated or not with CD40 ligand (CD40L). Elutriated monocytes were allowed to mature into macrophages for 7 days in the presence or absence of CD40L and then were infected with 300 TCID 50 of HIV-1 Ba-L . Relative HIV-1 DNA content was assessed 48 h after infection, using either long terminal repeat (LTR) R/U5 or SK38/SK39 gag primers. No amplified products were found in paired mock-infected samples used as negative controls and assayed undiluted (data not shown). The HLA-DQa1 DNA level was assessed as an amplification and DNA content control. Human placental DNA was used to normalize all samples to 1000 ng of DNA. Fluorescence-activated cell sorter analysis, which was done just before infection, demonstrated ,5% lymphocyte contamination, thus excluding that lymphocyte cell infection could contribute to the difference of HIV DNA content between control and CD40L macrophages. . Limiting-dilution polymerase chain reaction amplification of human immunodeficiency virus (HIV) type 1 DNA in HIV-1-infected macrophages cultured in the presence of macrophage colonystimulating factor (M-CSF) and stimulated or not with CD40 ligand (CD40L). Elutriated monocytes were cultured in the presence of M-CSF with or without CD40L for 7 days and then were infected with 300 TCID 50 of HIV-1 Ba-L . Relative HIV-1 DNA content was assessed 48 h after infection, using long terminal repeat (LTR) R/U5 primers. Paired mock-infected samples were used as negative controls and assayed undiluted. The HLA-DQa1 DNA level was assessed as an amplification and DNA content control. Human placental DNA was used to normalize all samples to 400 ng of DNA. 0.83 mM and 0.87 mM, respectively). We also explored the effect of CD40L on viral infection and/or antiviral activity of zidovudine and 23f in C8166, a T lymphocytic cell line. Neither increase in viral production nor decrease in the antiviral activity of zidovudine or 23f was seen (data not shown).
Discussion
We have determined the effects of CD40L on the expression of CD4 and the HIV-1 coreceptor CCR5, as well as on HIV-1 entry into and replication in human primary macrophages. Our results indicate that CD40L affects viral entry through modulation of CD4 and CCR5 expression. CD40L could not up-modulate productive viral infection; however, it increased overall viral production by prolonging the life span of infected macrophages.
In addition, CD40L down-regulated the antiviral efficacy of compounds that inhibit HIV-1 RT.
The interaction between CD40L and the CD40 receptor is critical for antigen-specific T cell responses [11, 12] . The ability of CD40/CD40L stimulation to regulate T cell-dependent responses is mediated, among other mechanisms, by enhancement of the expression of a number of molecules on the macrophage surface, including CD54, CD80, and CD86 [13] [14] . Thus, it is not surprising that CD40L stimulation of macrophages also increased the expression of CD4 and CCR5, 2 receptors that play an important role in the development of immunologic reactions. Also, up-regulation of CD4 and CCR5 expression was not mediated by M-CSF and GM-CSF, which were not increased, compared with control cells, in supernatants from CD40L-stimulated cultures. Figure 5 . Kinetics of human immunodeficiency virus (HIV) type 1 production by unstimulated and CD40 ligand (CD40L)-stimulated macrophages. Elutriated monocytes were allowed to mature into macrophages for 7 days in the presence or absence of CD40L and then were infected with 300 TCID 50 of the macrophage-trophic laboratory strain Ba-L or the macrophage-trophic clinical isolates FB1, FB2, and FB3. Viral replication was quantified by dosing HIV p24 antigen production in supernatants. At day 21, supernatants were further assayed by dosing reverse-transcriptase (RT) activity. Mean RT values at this time were as follows: Ba-L, 52,600 cpm/mL; Ba-L + CD40L, 48,600 cpm/mL; FB1, 32,800 cpm/ mL; FB1 + CD40L, 33,600 cpm/mL; FB2, 22,200 cpm/mL; FB2 + CD40L, 20,400 cpm/mL; FB3, 15,700 cpm/mL; and FB3 + CD40L, 18,200 cpm/mL. At day 21, HIV p24 antigen production by HIV-1 Ba-L -infected macrophages was significantly higher (P , :05) with respect to FB2-and FB3-infected cells. The average of 3 experiments, with 3 different donors, each carried out in triplicate, is reported. Error bars represent SEs.
In conflict with data presented here, Cotter et al. [22] and di Marzio et al. [23] recently reported that, in cultured macrophages, b-chemokines produced by CD40L stimulation reduce CD4 and CCR5 expression and inhibit HIV-1 entry. These seemingly conflicting data are probably due to variations related to the experimental procedures used to cultivate macrophages. In particular, Cotter et al. cultured macrophages with 1000 U/mL of M-CSF, whereas, di Marzio et al. allowed monocytes to mature into macrophages in the presence of human serum, which may contain up to 700-1000 U/mL M-CSF [41, 42] . As we have shown here, stimulation of macrophages with CD40L and M-CSF significantly reduces CD4 and CCR5 expression and HIV entry with respect to M-CSF alone. It is conceivable that decreased receptor expression in CD40L/M-CSF-stimulated macrophages, with respect to cells activated with M-CSF alone, resulted in less efficient infection by both, reduced susceptibility of macrophages to HIV-1, and increased inhibitory activity of the CD40L-induced b-chemokines, which directly compete with gp120 from macrophagetrophic HIV-1 strains for binding to CCR5 [43] . On the other hand, the CD40L-mediated up-modulation of CD4 and CCR5 found in our cultures allowed more efficient entry of HIV and counteracted the b-chemokine antiviral activity. M-CSF markedly affects membrane antigen expression by macrophages [31, 44] . Moreover, M-CSF can increase the susceptibility of macrophages to HIV infection [44, 45] .
In addition, Amzazi et al. [46] recently reported that b-chemokines had no anti-HIV effect in macrophages cultured in the presence of M-CSF. For these reasons, unstimulated macrophages, as those used here, may represent a more suitable control with respect to M-CSF-stimulated cells to study the capacity of CD40L to affect membrane antigen expression, susceptibility to HIV infection, and antiviral activity of b-chemokines. Nevertheless, further experiments are needed to determine which culture procedure is more relevant for the in vivo situation.
Our results are more consistent with those of other groups who showed that CD40L increases the expression of HIV-1 receptors and the susceptibility of monocyte-derived dendritic cells and B lymphocytes to HIV-1 infection [18, 19, 47] . However, it is puzzling why CD40L, which increased permissiveness of macrophages to HIV-1, did not also affect the efficiency of HIV-1 replication. A possible explanation is that replication of HIV-1 in CD40L-stimulated macrophages could be restricted at a step following DNA integration. This is consistent with the ability of CD40L to increase the activity of a recently discovered intracellular CD40-binding protein, termed TNF receptor-associated protein, that inhibits, in a dose-dependent manner, the transcriptional activation of NF-kB [48] , which mediates transactivation of the HIV LTR [49] .
The role of macrophages in the pathogenesis of HIV infection has been overstressed [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] ; thus, therapeutic strategies used in therapy for AIDS and related disorders should directly address the virus inhibition in this special target population. A variety of stimuli may affect the activity of anti-HIV agents in macrophages [50] . As shown in these experiments, CD40L reduced the antiviral activity of compounds that act at the level of the viral RT. It has been shown that the activity of antiviral drugs is highly dependent on virus load [51] ; thus, CD40L may be affecting the efficacy of these compounds by increasing viral entry and HIV DNA synthesis. In contrast, CD40L stimulation of macrophages had essentially no effect on the anti-HIV activity of substances that NOTE. At day 0, 200,000 monocytes were plated. Cells were allowed to mature into macrophages for 7 days in the presence or absence of CD40L and then were infected with the macrophage-trophic laboratory strain Ba-L. The no. of live cells was determined by trypan blue assay. Propidium iodide staining and flow cytometric (FACS) analysis were used to quantify the percentage of necrotic cells. The percentage of HIV p24-positive cells was assessed by FACS analysis. Data were calculated on bivariate dot plots, with the quadrants set according to the negative controls (, 1% of the isotype control cells appeared to be positive). Five thousand cells were analyzed for each sample. The data shown are representative of 3 experiments that were performed with similar results. Figure 6 . Effect of CD40 ligand (CD40L) on ongoing viral production. Elutriated monocytes were allowed to mature into macrophages for 7 days in the absence of CD40L and then were infected with 300 TCID 50 of the macrophage-trophic laboratory strain Ba-L; 24 h after viral infection, 1 mg/mL CD40L was added to the cultures. Viral replication was quantified by dosing human immunodeficiency virus (HIV) p24 antigen production in supernatants. The average of 2 experiments, with 2 different donors, each carried out in triplicate, is reported. Error bars represent SEs. affect postintegrational steps of HIV replication, such as the HIV protease inhibitor U75875. This is consistent with the absence of an effect of CD40L stimulation on viral output, the functional equivalent of an increase in virus load for the HIV protease inhibitor U75875, of which the mechanism of action is directed at inhibiting only postintegrational stages of the HIV life cycle.
As shown here, CD40L stimulation of macrophages resulted in increased HIV-1 entry and viral DNA synthesis and integration. Moreover, although CD40L could not directly modulate HIV-1 replication, it increased overall viral production by enhancing the survival of infected cells and strongly reduced the anti-HIV activity of compounds that compete with viral RT. Considering that HIV-1 infection is associated with chronic antigenic stimulation [52] , that CD40/CD40L interactions are associated with this process, that CD40 is strongly expressed on the surface of macrophages in lymphoid organs [53] , that most HIV-1-infected macrophages are found in lymphoid tissue [3, 4] , and that drugs that inhibit RT are currently used to treat HIV-infected patients, it is likely that our ex vivo model is reflecting events that take place in vivo during the course of HIV-1 disease. Thus, CD40L stimulation of macrophages may both contribute to plasma virus load and favor the establishment of a pool of latently infected macrophages that can be reactivated to release virus.
On the other hand, there are data showing restoration of defective IL-12 in HIV-1-infected macrophages by CD40L stimulation [16] , thereby suggesting reasons to pursue CD40L to replace deficient helper function in HIV-1-infected individuals. Further work is needed to determine the relative importance of CD40L-induced increased permissiveness of macrophages to HIV-1 versus restoration of immune functions with respect to HIV-1 pathogenesis.
